---
title: "SARS-CoV-2 antibody landscape after multiple Omicron-era vaccinations and infections"
id: "medrxiv-23-sars-cov-2-antibody-landscape-following-multiple-vaccinations-and-infections"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-23-sars-cov-2-antibody-landscape-following-multiple-vaccinations-and-infections"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.16.26368199v1?rss=1"
published_at: "2026-11-18T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# SARS-CoV-2 antibody landscape after multiple Omicron-era vaccinations and infections
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-23-sars-cov-2-antibody-landscape-following-multiple-vaccinations-and-infections
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.16.26368199v1?rss=1)
- **Published At:** 2026-11-18T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The investigators sampled participants from a Michigan prospective cohort who had received at least five COVID-19 vaccine doses between 2020 and 2025. The cohort size reported was 21 participants, with a median of seven vaccine doses. - Serum measurements used multiplex assays to quantify **IgG**, IgM, and **ACE2** percent inhibition across ancestral and Omicron strains. Regression models were applied for baseline-adjusted immunogenicity, cross-reactivity, and formulation-specific durability. - For every two-fold higher pre-vaccination **IgG**, the post-vaccination fold-rise was reduced: 34% lower after monovalent (95% CI: 16%–48%), 43% lower after bivalent (95% CI: 15%–62%), and 55% lower after 2023–24 vaccination (95% CI: 21%–75%). - Baseline-adjusted immunogenicity did not show consistent trends across successive vaccine doses, indicating maintained post-dose responses despite complex immune histories. - Antibody landscapes demonstrated broad cross-reactivity against ancestral and Omicron variants with similar strain-specific **IgG** changes across matched and antigenically distant strains; **ACE2** inhibition showed greater heterogeneity. - Waning models found significant **IgG** declines after monovalent (beta = -1.03; 95% CI: -1.51 to -0.55; P<0.001) and bivalent vaccination (beta = -1.00; 95% CI: -1.71 to -0.30; P=0.007). **ACE2** inhibition declined following monovalent vaccination; other formulations produced less consistent changes. - Despite measurable waning, antibody levels generally remained relatively high across variants up to 300 days post-vaccination, with differences in durability by formulation. - The authors noted no direct conflicts related to this work and documented University of Michigan IRB approval; data are available on request under controlled access per CEIRR network procedures.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=HuYjXVXIAQHXIKd2HsMFKK5_iSSLJG4GerVOdik3lAw-1795056710.623724-1.2.1.1-q3esPF_FoKdZTkM3gKveZQKHooZyZ6MPa1OfIbQrcVnDaY7PBP.xI3X6Qsg9Maap) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.16.26368199v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # SARS-CoV-2 antibody landscape following multiple vaccinations and infections during Omicron period [ View ORCID Profile](http://orcid.org/0000-0002-6011-4152)Yangyupei Yang, Casey Juntila-Raymond, Amy Callear, Matthew Smith, Elie-Tino Godonou, Arnold S. Monto, Emily T. Martin doi: https://doi.org/10.64898/2026.11.16.26368199 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Yangyupei Yang 1 Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Yangyupei%2BYang%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Yang%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AYangyupei%2BYang%2B) * [ORCID record for Yangyupei Yang](http://orcid.org/0000-0002-6011-4152 "Open in new tab") * For correspondence: jadeyang@umich.edu Casey Juntila-Raymond 2 Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA. * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Casey%2BJuntila-Raymond%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Juntila-Raymond%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACasey%2BJuntila-Raymond%2B) Amy Callear 2 Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA. * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amy%2BCallear%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Callear%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAmy%2BCallear%2B) Matthew Smith 2 Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA. * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Matthew%2BSmith%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Smith%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMatthew%2BSmith%2B) Elie-Tino Godonou 2 Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA. * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Elie-Tino%2BGodonou%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Godonou%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AElie-Tino%2BGodonou%2B) Arnold S. Monto 2 Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA. * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Arnold%2BS.%2BMonto%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Monto%20AS&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AArnold%2BS.%2BMonto%2B) Emily T. Martin 2 Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA. * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Emily%2BT.%2BMartin%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Martin%20ET&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEmily%2BT.%2BMartin%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.16.26368199v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1348181/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.16.26368199v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1348181/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.16.26368199v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1348181/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.11.16.26368199v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1348181/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.16.26368199v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1348181/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.16.26368199v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1348181/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: Repeated COVID-19 vaccination effects on the immunogenicity, breadth, and durability of antibody responses across antigenically distinct SARS-CoV-2 variants remain incompletely understood. Method: Participants receiving >= five COVID-19 vaccine doses 2020-2025 were selected from a prospective cohort in Michigan. Serum IgG, IgM, and ACE2 percent inhibition were measured using multiplex assays. Baseline-adjusted immunogenicity, cross-reactivity, and formulation-specific antibody durability were evaluated using regression models. Result: Twenty-one participants were included (median: seven vaccine doses). For every two-fold increase in pre-vaccination IgG concentration, post-vaccination fold-rise was 34% (95% CI: 16%-48%), 43% (95% CI: 15%-62%), and 55% (95% CI: 21%-75%) lower following monovalent, bivalent, and 2023-24 vaccination, while baseline-adjusted immunogenicity showed no significant trends across successive vaccines. Antibody landscapes demonstrated broad cross-reactivity against ancestral and Omicron variants, with similar strain-specific IgG changes across ancestral, vaccine-matched, and antigenically distant strains, but greater heterogeneity in ACE2 inhibition. Formulation-specific waning models showed significant IgG declines following monovalent and bivalent vaccination (beta = -1.03, 95% CI: -1.51 to -0.55; P The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.16.26368199v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.16.26367283v1 "A Whole-Blood Four-Gene Panel Distinguishes Pediatric Crohn's Disease from Disorders of Gut-Brain Interaction")[Next ](https://www.medrxiv.org/content/10.64898/2026.11.16.26368102v1 "Swab-based molecular testing near the point-of-care for childhood tuberculosis: a prospective diagnostic accuracy study") Posted November 18, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.16.26368199v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/18/2026.11.16.26368199.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.16.26368199v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.11.16.26368199v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/18/2026.11.16.26368199.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) SARS-CoV-2 antibody landscape following multiple vaccinations and infections during Omicron period Yangyupei Yang, Casey Juntila-Raymond, Amy Callear, Matthew Smith, Elie-Tino Godonou, Arnold S. Monto, Emily T. Martin medRxiv 2026.11.16.26368199; doi: https://doi.org/10.64898/2026.11.16.26368199 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.16.26368199v1%26text%3DSARS-CoV-2%2520antibody%2520landscape%2520following%2520multiple%2520vaccinations%2520and%2520infections%2520during%2520Omicron%2520period "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.16.26368199v1%26t%3DSARS-CoV-2%2520antibody%2520landscape%2520following%2520multiple%2520vaccinations%2520and%2520infections%2520during%2520Omicron%2520period "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.16.26368199v1%26title%3DSARS-CoV-2%2520antibody%2520landscape%2520following%2520multiple%2520vaccinations%2520and%2520infections%2520during%2520Omicron%2520period%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.16.26368199v1%26title%3DSARS-CoV-2%2520antibody%2520landscape%2520following%2520multiple%2520vaccinations%2520and%2520infections%2520during%2520Omicron%2520period "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.11.16.26368199) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.11.16.26368199v1&count=horizontal&via=&text=SARS-CoV-2%20antibody%20landscape%20following%20multiple%20vaccinations%20and%20infections%20during%20Omicron%20period&counturl=www.medrxiv.org/content/10.64898/2026.11.16.26368199v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (642) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (925) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (355) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (5049) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (496) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (431) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (681) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1703) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16330) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (37) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1247) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7315) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (758) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1100) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5334) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1480) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1845) * [Hematology](https://www.medrxiv.org/collection/hematology) (601) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1387) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16528) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1207) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (702) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (157) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (755) * [Neurology](https://www.medrxiv.org/collection/neurology) (7652) * [Nursing](https://www.medrxiv.org/collection/nursing) (380) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1140) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1303) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1045) * [Oncology](https://www.medrxiv.org/collection/oncology) (3760) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1103) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (413) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (472) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (506) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (144) * [Pathology](https://www.medrxiv.org/collection
## Related Clinical Research

- [Near-point-of-care CRP and SAA meet WHO target product profile for TB screening](https://medichelpline.com/clinical-feed/medrxiv-4-near-point-of-care-c-reactive-protein-and-serum-amyloid-a-test-met-who-target.md)
- [Self-reported tuberculosis prevalence and vulnerability factors in six rural Indian districts](https://medichelpline.com/clinical-feed/plos-one-16-self-reported-prevalence-of-tuberculosis-and-selected-associated-vulnerability.md)
- [ACE2 Polymorphisms rs2285666 and rs147311723 Linked to Inflammation in COVID‑19 and TB Co‑infection](https://medichelpline.com/clinical-feed/medrxiv-21-ace2-polymorphisms-rs2285666-and-rs147311723-are-clinically-relevant-variants.md)
- [Burden of RSV Hospitalizations in Brazilian Adults Aged ≥60 Years (2013–2024)](https://medichelpline.com/clinical-feed/pubmed-42758792.md) (DOI: 10.1371/journal.pone.0357303)
- [Leveraging MAHA and Kennedy to Combat Measles Vaccine Hesitancy](https://medichelpline.com/clinical-feed/stat-news-0-opinion-how-kennedy-and-maha-could-help-stop-measles.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.